MSMarielle Scherrer-Crosbie

Marielle Scherrer-Crosbie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marielle Scherrer-Crosbie has a total of 189 co-authors. Here are the top co-authors by number of shared publications:

  • Michael H. Picard

    Massachusetts General Hospital

    16 shared publications
  • Elkan F. Halpern

    Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts

    11 shared publications
  • Kenneth D. Bloch

    Anesthesia Center for Critical Care Research, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

    10 shared publications
  • Emmanuel S. Buys

    Anesthesia Center for Critical Care Research, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

    7 shared publications
  • Michael J. Raher

    Anesthesia Center for Critical Care Research, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

    7 shared publications
  • Timothy C. Tan

    Blacktown Clinical School, Department of Cardiology, Faculty of Medicine, University of Western Sydney, and School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, Australia

    6 shared publications

Latest Publications

  • Adverse impact of diabetes mellitus on left ventricular remodelling in patients with chronic primary mitral regurgitation

    by Laura Ernande, Jonathan Beaudoin, Victoria Piro, Souhila Meziani, Marielle Scherrer-Crosbie


  • Acute Leukemia is Associated with Cardiac Alterations before Chemotherapy

    by Bruna Morhy Borges Leal Assuncao, Mark D. Handschumacher, Andrew M. Brunner, Evin Yucel, Philipp E. Bartko, Kai-Hung Cheng, Orlando Campos, Amir T. Fathi, Timothy C. Tan, Marielle Scherrer-Crosbie


  • Contraction Timing Patterns in Patients Treated for Breast Cancer Before and After Anthracyclines Therapy

    by Kai-Hung Cheng, Mark D. Handschumacher, Bruna Morhy Borges Leal Assuncao, Igal A. Sebag, Elkan F. Halpern, Marielle Scherrer-Crosbie


  • CHANGES IN CITRIC ACID METABOLISM ARE ASSOCIATED WITH THE DEVELOPMENT OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN MICE AND IN PATIENTS

    by Aarti Asnani, Xu Shi, Laurie Farrell, Robert Tainsh, Sara Vandenwijngaert, Kai-Hung Cheng, Emmanuel Buys, Robert Gerszten, Marielle Scherrer-Crosbie


  • Brown adipose tissue: The heat is on the heart

    by Robrecht Thoonen, Allyson G. Hindle, Marielle Scherrer-Crosbie

    The study of brown adipose tissue (BAT) has gained significant scientific interest since the discovery of functional BAT in adult humans. The thermogenic properties of BAT are well recognized; however, data generated in the last decade in both rodents and humans reveal therapeutic potential for BAT against metabolic disorders and obesity. Here we review the current literature in light of a potential role for BAT in beneficially mediating cardiovascular health. We focus mainly on BAT's actions in obesity, vascular tone, and glucose and lipid metabolism. Furthermore, we discuss the recently discovered endocrine factors that have a potential beneficial role in cardiovascular health. These BAT-secreted factors may have a favorable effect against cardiovascular risk either through their metabolic role or by directly affecting the heart.


  • Myocardial Strain Is Associated with Adverse Clinical Cardiac Events in Patients Treated with Anthracyclines

    by Mohammed T. Ali, Evin Yucel, Souhila Bouras, Lin Wang, Hong-Wen Fei, Elkan F. Halpern, Marielle Scherrer-Crosbie


  • Relationship of brown adipose tissue perfusion and function: a study through β2-adrenoreceptor stimulation

    by Laura Ernande, Kristin I. Stanford, Robrecht Thoonen, Haihua Zhang, Maëva Clerte, Michael F. Hirshman, Laurie J. Goodyear, Kenneth D. Bloch, Emmanuel S. Buys, Marielle Scherrer-Crosbie

    Brown adipose tissue (BAT) activation increases glucose and lipid consumption; as such, it is been considered as a potential therapy to decrease obesity. BAT is highly vascularized and its activation is associated with a necessary increase in blood flow. However, whether increasing BAT blood flow per se increases BAT activity is unknown. To examine this hypothesis, we investigated whether an isolated increase in BAT blood flow obtained by β2-adrenoreceptor (β2-AR) stimulation with salbutamol increased BAT activity. BAT blood flow was estimated in vivo in mice using contrast-enhanced ultrasound. The absence of direct effect of salbutamol on the function of isolated brown adipocytes was assessed by measuring oxygen consumption. The effect of salbutamol on BAT activity was investigated by measuring BAT glucose uptake in vivo. BAT blood flow increased by 2.3 ± 0.6-fold during β2-AR stimulation using salbutamol infusion in mice (P = 0.003). β2-AR gene expression was detectable in BAT but was extremely low in isolated brown adipocytes. Oxygen consumption of isolated brown adipocytes did not change with salbutamol exposure, confirming the absence of a direct effect of β2-AR agonist on brown adipocytes. Finally, β2-AR stimulation by salbutamol increased BAT glucose uptake in vivo (991 ± 358 vs. 135 ± 49 ng glucose/mg tissue/45 min in salbutamol vs. saline injected mice, respectively, P = 0.046). In conclusion, an increase in BAT blood flow without direct stimulation of the brown adipocytes is associated with increased BAT metabolic activity. Increasing BAT blood flow might represent a new therapeutic target in obesity.


  • Left Ventricular Global Longitudinal Strain in HER‐2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction

    by Hong‐Wen Fei, Mohammed T. Ali, Timothy C. Tan, Kai‐Hung Cheng, Laura Salama, Lanqi Hua, Xin Zeng, Elkan F. Halpern, Alphonse Taghian, Shannon M. MacDonald, et al.

    Aim: The combination of anthracyclines (AC) and trastuzumab (TRZ) is highly effective in patients with aggressive HER‐2 + breast cancer, but has a significant risk of cardiotoxicity (CT). Trastuzumab‐induced CT may be reversible. The aim of this study was to identify echocardiographic parameters associated with recovery of left ventricular ejection fraction (LVEF) in patients who developed CT after AC and TRZ treatment.Methods and Results: Women with newly diagnosed breast cancer treated with AC followed by TRZ and monitored with serial echocardiograms were retrospectively studied. Left ventricular end‐diastolic and systolic volumes, LVEF, and global longitudinal strain (GLS) were examined. Development and reversibility of CT were defined based on changes in LVEF according to the 2014 ASE/EACVI recommendations. Cox analysis was used to determine the association of echocardiographic variables with the subsequent development and reversibility of CT. Ninety‐five patients underwent 5 echocardiograms or more in a 17‐month (13–28 months) follow‐up period. Nineteen patients (20%) developed CT. Left ventricular volumes, LVEF, and GLS measured after AC completion identified the subsequent development of CT. Of the 19 patients with CT, the LVEF partially or fully recovered in 13 (68%). GLS at the time of CT diagnosis was associated with subsequent recovery of LVEF (P = 0.004).Conclusion: In patients with breast cancer treated with AC and TRZ who develop CT, GLS at the time of CT diagnosis is associated with subsequent recovery of LVEF and may be useful for risk stratification and to guide treatment.


  • Open Access

    The value of core lab stress echocardiography interpretations: observations from the ISCHEMIA Trial

    by Akihisa Kataoka, Marielle Scherrer-Crosbie, Roxy Senior, Gilbert Gosselin, Denis Phaneuf, Gabriela Guzman, Gian Perna, Alfonso Lara, Sasko Kedev, Andrea Mortara, et al.

    Stress echocardiography (SE) is dependent on subjective interpretations. As a prelude to the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial, potential sites were required to submit two SE, one with moderate or severe left ventricular (LV) myocardial ischemia and one with mild ischemia. We evaluated the concordance of site and core lab interpretations. Eighty-one SE were submitted from 41 international sites. Ischemia was classified by the number of new or worsening segmental LV wall motion abnormalities (WMA): none, mild (1 or 2) or moderate or severe (3 or more) by the sites and the core lab. Core lab classified 6 SE as no ischemia, 35 mild and 40 moderate or greater. There was agreement between the site and core in 66 of 81 total cases (81 %, weighted kappa coefficient [K] =0.635). Agreement was similar for SE type - 24 of 30 exercise (80 %, K = 0.571) vs. 41 of 49 pharmacologic (84 %, K = 0.685). The agreement between poor or fair image quality (27 of 36 cases, 75 %, K = 0.492) was not as good as for the good or excellent image quality cases (39 of 45 cases, 87 %, K = 0.755). Differences in concordance were noted for degree of ischemia with the majority of discordant interpretations (87 %) occurring in patients with no or mild LV myocardial ischemia. While site SE interpretations are largely concordant with core lab interpretations, this appears dependent on image quality and the extent of WMA. Thus core lab interpretations remain important in clinical trials where consistency of interpretation across a range of cases is critical. ClinicalTrials.gov NCT01471522


  • Regulation of B‐type natriuretic peptide synthesis by insulin in obesity in male mice

    by Haihua Zhang, Robrecht Thoonen, Vincent Yao, Emmanuel S. Buys, John Popovich, Yan Ru Su, Thomas J. Wang, Marielle Scherrer‐Crosbie

    New Findings: What is the central question of this study? The plasma concentration of brain natriuretic peptide (BNP) is decreased in obesity, a finding that may be deleterious from a cardiovascular, renal and metabolic standpoint. The present study used a mouse model of high‐fructose, high‐fat (HFHF) diet and isolated cardiomyocytes to investigate the mechanisms involved in this decrease. What is the main finding and its importance? The gene expression level of BNP is decreased in the left ventricle of mice fed a HFHF diet for 4 weeks and in cardiomyocytes exposed to prolonged high doses of insulin. A decrease in BNP synthesis may contribute to the decreased BNP plasma concentrations observed in obesity and insulin resistance. Human studies suggest that insulin resistance and obesity are associated with a decrease in B‐type natriuretic peptide (BNP) plasma concentrations. The objective of the study was to gain insights into the mechanisms involved in the association between insulin resistance and decreased BNP plasma concentrations. Mice fed a high‐fat, high‐fructose (HFHF) diet for 4 weeks developed mild obesity and systemic insulin resistance. Elevated plasma concentrations of insulin, glucose and triglycerides were noted. The HFHF diet was also associated with myocardial insulin resistance, characterized by an impaired response of the phosphoinositide 3‐kinase–AKT (PI3K–AKT) pathway to insulin in the left ventricle. Myocardial BNP expression and protein were decreased in HFHF‐fed mice compared with control animals. Exposure of cardiomyocytes to 100 nm insulin activated PI3K–AKT signalling (15 min) and induced a 1.9 ± 0.3‐fold increase in BNP gene expression (6 h). Prolonged exposure of cardiomyocytes to a high insulin concentration (100 nm) for 48 h induced insulin resistance, characterized by an impaired response of the PI3K–AKT signalling pathway and a decreased response of the BNP gene expression to insulin. The decreased response in BNP gene expression was reproduced by treating cardiomyocytes for 7 h with a PI3‐kinase inhibitor (wortmannin). In conclusion, HFHF diet in vivo, prolonged exposure to an elevated concentration of insulin or inhibition of the PI3K–AKT pathway in vitro all decrease BNP mRNA levels; this decrease may in turn contribute to the decreased BNP peptide concentrations in plasma observed in insulin‐resistant individuals.